CN117017850A - 一种祛痘修复的外用化妆品组合物及其应用 - Google Patents
一种祛痘修复的外用化妆品组合物及其应用 Download PDFInfo
- Publication number
- CN117017850A CN117017850A CN202310860991.XA CN202310860991A CN117017850A CN 117017850 A CN117017850 A CN 117017850A CN 202310860991 A CN202310860991 A CN 202310860991A CN 117017850 A CN117017850 A CN 117017850A
- Authority
- CN
- China
- Prior art keywords
- parts
- acne
- extract
- sodium
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 140
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 129
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 239000002537 cosmetic Substances 0.000 title claims abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 65
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims abstract description 48
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims abstract description 24
- 244000064816 Brassica oleracea var. acephala Species 0.000 claims abstract description 24
- 240000009085 Nymphaea caerulea Species 0.000 claims abstract description 22
- 235000002195 Nymphaea caerulea Nutrition 0.000 claims abstract description 22
- 229940084038 salix alba bark extract Drugs 0.000 claims abstract description 19
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 17
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 17
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940036350 bisabolol Drugs 0.000 claims abstract description 17
- 230000008439 repair process Effects 0.000 claims abstract description 15
- 241000416162 Astragalus gummifer Species 0.000 claims abstract description 13
- 229920001615 Tragacanth Polymers 0.000 claims abstract description 13
- 239000000196 tragacanth Substances 0.000 claims abstract description 13
- 235000010487 tragacanth Nutrition 0.000 claims abstract description 13
- 229940116362 tragacanth Drugs 0.000 claims abstract description 13
- 239000000839 emulsion Substances 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- -1 pH regulators Substances 0.000 claims description 18
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 240000000073 Achillea millefolium Species 0.000 claims description 9
- 235000007754 Achillea millefolium Nutrition 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 8
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 8
- 229940075529 glyceryl stearate Drugs 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 7
- 229960005323 phenoxyethanol Drugs 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 4
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 229960003237 betaine Drugs 0.000 claims description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 4
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000004088 foaming agent Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 4
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 229940100460 peg-100 stearate Drugs 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 206010040882 skin lesion Diseases 0.000 claims description 4
- 231100000444 skin lesion Toxicity 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229940083542 sodium Drugs 0.000 claims description 4
- 229940032094 squalane Drugs 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 3
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229960002255 azelaic acid Drugs 0.000 claims description 3
- 229940073499 decyl glucoside Drugs 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- KAKVFSYQVNHFBS-UHFFFAOYSA-N (5-hydroxycyclopenten-1-yl)-phenylmethanone Chemical compound OC1CCC=C1C(=O)C1=CC=CC=C1 KAKVFSYQVNHFBS-UHFFFAOYSA-N 0.000 claims description 2
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 2
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 2
- OUNZARDETXBPIX-UHFFFAOYSA-N 2-(2-dodecoxyethoxy)acetic acid Chemical compound CCCCCCCCCCCCOCCOCC(O)=O OUNZARDETXBPIX-UHFFFAOYSA-N 0.000 claims description 2
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 claims description 2
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 2
- DDGPBVIAYDDWDH-UHFFFAOYSA-N 3-[dodecyl(dimethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC(O)CS([O-])(=O)=O DDGPBVIAYDDWDH-UHFFFAOYSA-N 0.000 claims description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001534 FEMA 4201 Substances 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 229920002651 Polysorbate 85 Polymers 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 241000736131 Sphingomonas Species 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- ATMLPEJAVWINOF-UHFFFAOYSA-N acrylic acid acrylic acid Chemical compound OC(=O)C=C.OC(=O)C=C ATMLPEJAVWINOF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 229940071120 dehydroacetate Drugs 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940113120 dipropylene glycol Drugs 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 229960005082 etohexadiol Drugs 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 2
- 229960002160 maltose Drugs 0.000 claims description 2
- 229940105132 myristate Drugs 0.000 claims description 2
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- 229940032076 peg-15 glyceryl stearate Drugs 0.000 claims description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 2
- 229940097941 polyglyceryl-10 laurate Drugs 0.000 claims description 2
- 229940061570 polyglyceryl-10 stearate Drugs 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940113171 polysorbate 85 Drugs 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 claims description 2
- 108700004121 sarkosyl Proteins 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 229940065859 sodium cocoyl glycinate Drugs 0.000 claims description 2
- 229940079776 sodium cocoyl isethionate Drugs 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 229940057950 sodium laureth sulfate Drugs 0.000 claims description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 2
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 claims description 2
- IKGKWKGYFJBGQJ-UHFFFAOYSA-M sodium;2-(dodecanoylamino)acetate Chemical compound [Na+].CCCCCCCCCCCC(=O)NCC([O-])=O IKGKWKGYFJBGQJ-UHFFFAOYSA-M 0.000 claims description 2
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 claims description 2
- CAVXVRQDZKMZDB-UHFFFAOYSA-M sodium;2-[dodecanoyl(methyl)amino]ethanesulfonate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CCS([O-])(=O)=O CAVXVRQDZKMZDB-UHFFFAOYSA-M 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229940104261 taurate Drugs 0.000 claims description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 2
- 230000008719 thickening Effects 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 229940074410 trehalose Drugs 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims 1
- 241000195940 Bryophyta Species 0.000 claims 1
- 239000004909 Moisturizer Substances 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229940100524 ethylhexylglycerin Drugs 0.000 claims 1
- 229930182478 glucoside Natural products 0.000 claims 1
- 150000008131 glucosides Chemical class 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 235000011929 mousse Nutrition 0.000 claims 1
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 229940114926 stearate Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 abstract description 15
- 206010061218 Inflammation Diseases 0.000 abstract description 14
- 241000894006 Bacteria Species 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 8
- 230000028327 secretion Effects 0.000 abstract description 7
- 208000020154 Acnes Diseases 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 239000004519 grease Substances 0.000 abstract description 5
- 231100000344 non-irritating Toxicity 0.000 abstract description 5
- 239000000419 plant extract Substances 0.000 abstract description 4
- 208000028990 Skin injury Diseases 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 230000003467 diminishing effect Effects 0.000 abstract description 3
- 238000005562 fading Methods 0.000 abstract description 3
- 206010040880 Skin irritation Diseases 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 230000036556 skin irritation Effects 0.000 abstract 1
- 231100000475 skin irritation Toxicity 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 43
- 230000000694 effects Effects 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 238000012360 testing method Methods 0.000 description 19
- 208000012641 Pigmentation disease Diseases 0.000 description 18
- 230000019612 pigmentation Effects 0.000 description 17
- 206010015150 Erythema Diseases 0.000 description 14
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- 230000003255 anti-acne Effects 0.000 description 14
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 231100000321 erythema Toxicity 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229930003935 flavonoid Natural products 0.000 description 8
- 235000017173 flavonoids Nutrition 0.000 description 8
- 241000186427 Cutibacterium acnes Species 0.000 description 7
- 229940055019 propionibacterium acne Drugs 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 231100000241 scar Toxicity 0.000 description 7
- 239000003098 androgen Substances 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000003780 keratinization Effects 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 4
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 150000004032 porphyrins Chemical class 0.000 description 4
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 4
- 229940120668 salicin Drugs 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 229920000832 Cutin Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005282 brightening Methods 0.000 description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229930182486 flavonoid glycoside Natural products 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000124033 Salix Species 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008809 cell oxidative stress Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229950009829 prasterone sulfate Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 1
- PAEMERHSTIDLSE-VEIQOZLZSA-N (3r,4s,5s,6r)-2-hexadecoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PAEMERHSTIDLSE-VEIQOZLZSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- QYIMSPSDBYKPPY-BANQPHDMSA-N 2,3-epoxysqualene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC1OC1(C)C QYIMSPSDBYKPPY-BANQPHDMSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010046742 Urticaria contact Diseases 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940105017 achillea millefolium extract Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- KTYVHLCLTPLSGC-UHFFFAOYSA-N amino propanoate Chemical compound CCC(=O)ON KTYVHLCLTPLSGC-UHFFFAOYSA-N 0.000 description 1
- 230000009604 anaerobic growth Effects 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000341 effect on erythema Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000033785 sebaceous gland development Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cosmetics (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
本发明涉及化妆品技术领域,具体公开了一种外用的化妆品组合物。所述组合物包括以下重量份数的有效性组分:壬二酸0.1‑30份、红没药醇0.01‑2份、白柳树皮提取物0.01‑5份、埃及蓝睡莲花提取物0.01‑5份、羽衣甘蓝提取物0.01‑5份和欧蓍草提取物0.1‑5份。本发明还提供该组合物的用途,其具有抑菌消炎、改善皮肤油脂分泌的作用,从而可以用于祛痘、淡化痘印,以及修复痤疮导致的各种皮肤损伤,以及用于制备各种外用化妆品制剂,例如用于抗痘修复的精华液、乳液、面霜等。此外,组合物含有的有效成分包含天然植物提取物,能有效减少壬二酸对皮肤的刺激作用,并帮助组合物保持温和、无刺激的良好肤感。
Description
技术领域
本发明涉及化妆品领域,具体涉及一种可以祛痘修复的外用化妆品组合物及其应用。
背景技术
痤疮是一种好发于青春期并主要累及面部的毛囊皮脂腺单位慢性炎症性皮肤病,确切的发病机制仍未完全阐明。遗传、雄激素诱导的皮脂大量分泌、毛囊皮脂腺导管角化、痤疮丙酸杆菌繁殖、炎症和免疫反应等因素都可能与之相关。
雄激素作用下的皮脂腺快速发育和脂质大量分泌是痤疮发生的病理生理基础。进入青春期后肾上腺和性腺的发育导致雄激素前体如硫酸脱氢表雄酮(DHEAs)分泌增加,并在一系列雄激素代谢酶如5α还原酶的作用下转化为有活性的二氢睾酮,刺激皮脂腺功能增强。遗传背景下的皮肤内雄激素受体或相关雄激素代谢酶的表达或活性增强也是导致皮脂腺对雄激素过度敏感及脂质过量分泌的重要因素之一。此外,痤疮患者皮脂中存在过氧化鲨烯、蜡酯、游离脂肪酸含量增加,不饱和脂肪酸的比例增加及亚油酸含量降低等脂质成分改变,这些变化可以导致皮肤屏障功能受损、毛囊皮脂腺导管的角化及炎症反应。
毛囊皮脂腺导管异常角化是痤疮发生另一重要因素和主要病理现象。上皮细胞角化使毛囊皮脂腺导管堵塞、皮脂排出障碍,最终形成显微镜下可见的微粉刺及临床肉眼可见的粉刺,促炎症因子白介素(IL)-1α、雄激素、游离脂肪酸及过氧化脂质可能与导管角化异常有关。
痤疮丙酸杆菌与痤疮发生密切相关。微粉刺及粉刺的形成为具有厌氧生长特性的痤疮丙酸杆菌增殖创造了良好的局部环境。目前认为,痤疮丙酸杆菌可能通过天然免疫、获得性免疫及直接诱导参与了痤疮炎症的发生发展。痤疮早期炎症可能是Toll样受体(TLR)介导的天然免疫反应所致,诱导促炎症因子尤其是IL-1α释放;随着疾病发展,获得性免疫反应放大了炎症过程,进一步导致炎症因子释放及中性粒细胞聚集;痤疮丙酸杆菌还可产生多肽类物质,直接诱发或加重炎症。在疾病后期,毛囊壁断裂,毛囊中的脂质、毛发等物质进入真皮,进一步加重了炎症反应。
研究发现,我国超过95%的人会有不同程度痤疮发生,痤疮发生后会有红印或黑印,甚至3%~7%痤疮患者会遗留瘢痕,这给患者的美观及身心健康带来较大影响。痤疮常见的后遗症包括痤疮后红斑、痤疮后色素沉着和痤疮后瘢痕。
痤疮后红斑:痤疮往往和炎症相伴随,当痤疮消退后,被撑大的血管并不会立刻收缩,炎症后血液流动也会变慢,红细胞和血小板易于局部聚集,造成循环不畅,皮损处血液会呈现深红色,即产生痤疮后红斑,即红色痘印;
痤疮后色素沉着:痤疮后色素沉着即为黑色痘印,这种沉着是炎性反应刺激皮肤色素合成增加而形成。通过内外界刺激,黑色素母体被激活形成黑色痘印;
由此可知,在发病初期,对痤疮进行有效、及时干预,防止其进一步发展恶化,并且在治疗后期,改善痤疮皮损状态,对痤疮后斑痕、色素沉着等进行缓解,具有重要的临床意义。然而,现有的祛痘组合物成分较为单一,多仅仅包含抗菌成分及舒缓成分,不能对痤疮消退后沉着的色素等进行治疗和缓解。亟待开发更多同时具备减轻红色痘印、黑色素沉着的祛痘组合物,在痤疮产生至消退的周期内进行全面治疗,减少痤疮后遗症的产生。
壬二酸是常见的有机酸类祛痘成分。然而,酸类成分对皮肤具有一定的刺激和破坏作用,随着组合物中酸类成分种类的增加、浓度的提高、停留时间的延长,发生不良反应的概率也随之上升。当组合物中酸浓度过高或整体配比不适宜时,患者使用过程中可能出现暂时性红斑、肿胀、刺痛、灼热等不适,甚至出现结痂、色素沉着、灼伤、糜烂、渗出、色素异常、反应性痤疮、粟丘疹、毛细血管扩张、接触性荨麻疹、瘢痕等不良反应。如何进行适当配比,在实现含酸类组合物效果最大化的前提下,减轻上述不良反应,保证组合物温和、具有良好肤感,同样是目前祛痘组合物亟待研究和解决的问题。
发明内容
本发明的目的在于克服上述现有技术的不足之处而提供一种保湿性和肤感良好,具有祛痘、治疗痤疮后遗症作用的祛痘组合物。一方面,该组合物能起到抑菌、减少痤疮菌数量、祛痘效果,另一方面,该组合物还能针对性降低痤疮后遗症的产生:该组合物可以抑制皮脂腺激活、加速角质脱落保持毛孔开放、抗氧化消炎减少炎症,最终起到有效治疗痤疮后遗症,实现全阶段痤疮治疗效果。
为实现上述目的,本发明采取的技术方案为:
第一方面,本发明提供一种外用的化妆品组合物。
在本发明的一种实施方式中,所述组合物包含:壬二酸、红没药醇、白柳树皮提取物、埃及蓝睡莲花提取物、羽衣甘蓝叶提取物和欧蓍草提取物;
在本发明的一种实施方式中,以组合物的重量份数计,该组合物包括:壬二酸0.01-30份、红没药醇0.01-2份、白柳树皮提取物0.01-5份、埃及蓝睡莲花提取物0.01-5份、羽衣甘蓝提取物0.01-5份和欧蓍草提取物0.1-5份;
在本发明的一种实施方式中,以组合物的重量份数计,该组合物包括:壬二酸0.1-20份、红没药醇0.01-1.5份、白柳树皮提取物0.1-4份、埃及蓝睡莲花提取物0.1-3份、羽衣甘蓝提取物0.1-3份和欧蓍草提取物0.1-3份;
其中所述白柳树皮提取物以柳树条上的柳树皮为原料,将原料剪成碎末,加入乙醇浸泡2至3天,取滤液旋蒸得固体,将固体溶解于水中得白柳树皮提取物。白柳树皮提取物主要成分是水杨苷,除此之外还含有黄酮化合物和酚类物质。其包含的主要活性成分具有以下主要作用:水杨苷是一种氧化酶抑制剂,并可以调控与皮肤衰老生物学过程相关的基因群,能够起到抗皱抗衰老功效,并能增加皮肤光泽度及弹性,其还常用于药品领域,以治疗发热,缓解骨关节炎痛和腰背疼痛;黄酮类化合物具有抗自由基和抗氧化作用,在防治心血管疾病,如防止动脉硬化、降低血脂和胆固醇及减少冠心病发病率等方面均具有良好的效果。
埃及蓝睡莲花提取物以蓝睡莲干花为原料,取蓝睡莲干花,用体积分数为70%乙醇回流提取3次,每次1h,合并提取液,减压浓缩至浸膏,减压干燥得70%乙醇提取物。将上述提取物使用大孔吸附树脂柱纯化,取30%乙醇洗脱液和50%乙醇洗脱液。埃及蓝睡莲花提取物富含17种氨基酸,并含有多种植物性多酚类、黄酮类化合物,如槲皮素、山奈酚、杨梅素等。现有技术表明,埃及蓝睡莲花提取物所含有的多酚类、黄酮类化合物具有ABTS自由基清除作用、抗氧化能力以及α-葡萄糖苷酶选择性抑制活性,可以起到优良的抗氧化及降糖活性,进而用作为食药同源植物应用于食品、医药等行业。
羽衣甘蓝叶提取物以干燥羽衣甘蓝叶为原料,将新鲜羽衣甘蓝叶洗净、晾干、粉碎过筛,得到羽衣甘蓝粉末。室温下,粉末中加入乙醇搅拌浸提6h。滤液离心后弃渣收集上清液,50℃真空减压旋转蒸发后,制备成羽衣甘蓝叶乙醇提取物。羽衣甘蓝叶提取物含有大量类胡萝卜素类的叶黄素,并富含黄酮醇、花青素等类黄酮物质。现有技术表明羽衣甘蓝叶提取物对细胞氧化应激存在保护作用,能够延缓氧化损伤所造成的细胞死亡以及细胞自身的氧化损伤,具有预防心血管疾病和调节免疫等生理功能;同时,其能抑制IL-8等炎性细胞因子的分泌,有助于控制氧化应激反应过程所触发的肠道炎性反应,缓解某些与炎症反应相关联的肠道疾病。
欧蓍草提取物以欧蓍草茎、叶、花为原料。取欧蓍草粉碎至60目得欧蓍草粉末,将上述粉末用质量浓度为90%的乙醇于65℃下提取2次,合并提取液,过滤,浓缩滤液成浸膏,用大孔树脂进行纯化,95%的乙醇洗脱,分段收集流出液,流出液浓缩成稠膏,制备得到欧蓍草提取物。欧蓍草提取物富含琥珀酸,延胡索酸,α-味喃甲酸等有机酸,并含有黄酮苷。现有技术表明,这些有机酸具有抗菌、消炎、解热镇痛的作用;黄酮苷则可以减少黑素小体转运和黑素细胞树突增长,从而来抑制黑色素转运至角质细胞,达到一定提亮肤色、改善色素沉着的效果;与此同时,欧蓍草提取物能有效抑制弹性蛋白酶,具有恢复皮肤纤维组织的弹性、平衡及加快皮肤细胞新陈代谢的功能。
在本发明的一种实施方式中,所述组合物还可以包含辅料;
在本发明的一种实施方式中,辅料可以选自保湿剂、乳化剂、发泡剂、pH调节剂、防腐剂和增稠剂中的一种或一种以上;
在本发明的一种实施方式中,保湿剂选自甘油、丙二醇、1,3丁二醇、1,2己二醇、戊二醇、双丙甘醇、海藻糖、甜菜碱、泛醇、烟酰胺、麦芽糖、β-葡聚糖、乳酸钠、聚乙烯吡咯烷酮、聚季铵盐-51、山梨醇、辛甘醇、乙基己基甘油、PEG-200、PEG-400、甘油聚醚-26中的一种或一种以上;
在本发明的一种实施方式中,乳化剂选自鲸蜡硬脂醇、鲸蜡硬脂醇聚醚-21、甘油硬脂酸酯、PEG-100硬脂酸酯、PEG-15甘油硬脂酸酯、PEG-20甘油硬脂酸酯、PEG-30甘油硬脂酸酯、PEG-40甘油硬脂酸酯、聚山梨醇酯-20、聚山梨醇酯-40、聚山梨醇酯-60、聚山梨醇酯-80、聚山梨醇酯-85、聚甘油-10二异硬脂酸酯、聚甘油-10二硬脂酸酯、聚甘油-10肉豆蔻酸酯、聚甘油-10异硬脂酸酯、聚甘油-10月桂酸酯、聚甘油-10硬脂酸酯、聚甘油-10油酸酯、聚甘油-5硬脂酸酯、山嵛醇聚醚-10、山嵛醇聚醚-20、山嵛醇聚醚-25、山嵛醇聚醚-30、鲸蜡硬脂基葡糖苷和山梨坦橄榄油酸酯中的一种或一种以上;
在本发明的一种实施方式中,pH调节剂选自柠檬酸、柠檬酸钠、氢氧化钠、脱氢乙酸钠钾的一种或一种以上;
在本发明的一种实施方式中,发泡剂选自椰油酰胺丙基甜菜碱、椰油酰甘氨酸钠、椰油酰氨基丙酸钠,椰油酰羟乙磺酸酯钠、月桂醇聚醚硫酸酯钠、月桂醇聚醚硫酸酯铵、月桂醇硫酸酯钠、椰油酰胺丙基羟基磺基甜菜碱、月桂酰肌氨酸钠、月桂酸钾、甲基椰油酰基牛磺酸钠、甲基月桂酰基牛磺酸钠、月桂醇聚醚-6羧酸钠、月桂醇聚醚-16、癸基葡糖苷、月桂基羟基磺基甜菜碱、椰油酰两性基二乙酸二钠中的一种或一种以上;
在本发明的一种实施方式中,防腐剂选自苯氧乙醇、对羟基苯乙酮、乙基己基甘油、辛甘醇、辛酰羟肟酸、1,2-己二醇和苯甲酸中的一种或一种以上;所述增稠选自卡波姆、丙烯酸(类)/C10-30烷醇丙烯酸酯交联聚合物、黄原胶、鞘氨醇单胞菌发酵提取物、羟乙基纤维素和丙烯酰二甲基牛磺酸铵/VP共聚物一种或一种以上;所述油脂为角鲨烷、异十六烷、碳酸二辛酯、氢化聚癸烯、氢化聚异丁烯、硅油、辛酸癸酸甘油三酯和异壬酸异壬酯中的一种或一种以上。
第二方面,本发明提供一种组合物用于制备祛痘、淡化痘印、修复皮肤损伤的化妆品的用途。
第三方面,本发明提供一种祛痘修护组合物用于制备一种水剂型化妆品、乳剂型化妆品、凝胶剂化妆品、敷贴型化妆品、气雾剂型化妆品及粉剂型化妆品;
在本发明的一种实施方式中,祛痘修护组合物用于制备祛痘修护乳液;
在本发明的一种实施方式中,祛痘修护乳液以祛痘修护组合物的重量份数计,包含以下组分:
壬二酸0.01-30份、红没药醇0.01-2份、白柳树皮提取物0.01-5份、埃及蓝睡莲花提取物0.01-5份、羽衣甘蓝提取物0.01-5份和欧蓍草提取物0.1-5份;辅料:水80-95份,PEG-100硬脂酸酯0.1-1份,甘油硬脂酸酯0.1-1份,角鲨烷0.5-2份,异十六烷0.5-1份,卡波姆0.02-0.2份,黄原胶0.001-0.1份,丁二醇1-5份,甘油1-5份,苯氧乙醇0.5-0.8份。
在本发明的一种实施方式中,祛痘修护乳液以祛痘修护组合物的重量份数计,包含以下组分:
壬二酸0.1-20份、红没药醇0.01-1.5份、白柳树皮提取物0.1-4份、埃及蓝睡莲花提取物0.1-3份、羽衣甘蓝提取物0.1-3份和欧蓍草提取物0.1-3份;
辅料:水80-95份,PEG-100硬脂酸酯0.1-1份,甘油硬脂酸酯0.1-1份,角鲨烷0.5-2份,异十六烷0.5-1份,卡波姆0.02-0.2份,黄原胶0.001-0.1份,丁二醇1-5份,甘油1-5份,苯氧乙醇0.5-0.8份。
与现有技术相比,本发明的有益效果是:
首先,本发明的壬二酸、红没药醇、4-萜品醇、水杨酸、白柳树皮提取物、埃及蓝睡莲花提取物、羽衣甘蓝叶提取物和欧蓍草提取物的祛痘、治疗痤疮后遗症作用尤为突出。具体地,各组分可以单独或协同发挥作用,达到祛痘、治疗痤疮后遗症,即痤疮后红斑、痤疮后色素沉着和痤疮后瘢痕的效果:
壬二酸是一种具有抗菌、淡斑作用的护肤成分。从抗菌角度,壬二酸可以直接抑制和杀灭皮肤表面和毛囊内的细菌,对产生痤疮的细菌造成抑杀作用;从治疗痤疮后遗症角度,一方面,壬二酸可以抑制中性粒细胞释放活性氧,通过抗炎抗氧化抑制痤疮后红斑,即红色痘印的形成,另一方面,壬二酸可以抑制黑色素合成的二羧酸,进而抑制黑色素生成,改善痤疮后色素沉着。整体来看,壬二酸可以发挥多重作用协同,有效应对痤疮发展各个环节;红没药醇是一种来源于植物的倍半萜烯醇类天然产物,具有广谱抑菌、抗炎、修复性能的作用。红没药醇可以减少PMA引起的白三烯LTB4与白介素ⅠL-1α的释放,抑制炎症产生,进而减少痤疮后红斑的形成;同时,红没药醇具有修复作用,促进痤疮处皮肤的正常修复,防止痤疮后瘢痕的产生;4-萜品醇具有抑菌、抗氧化功能,对细菌、真菌均有抑制作用;除此之外,其还能显著抗氧化,帮助痤疮处皮肤迅速修复,防止痤疮后瘢痕的产生;水杨酸具有角质溶解、消炎的作用,其溶解皮肤表面的角质,疏通毛孔,皮脂正常排出,使痤疮丙酸杆菌大量繁殖失去基础,同时,在痤疮治疗消退后,水杨酸则发挥消炎作用,有效缓解痤疮后红斑;白柳树皮提取物的主要活性成分为水杨苷,水杨苷具有抗菌、消炎和修复作用。一方面,其具有的抗菌、消炎作用能抑制痤疮引起的炎症,有效缓解痤疮后红斑;另一方面,水杨苷对胶原蛋白的产生和维持有重要作用,能够促进痤疮部位皮肤的正常修复,降低痤疮后瘢痕的产生;
埃及蓝睡莲花提取物主要成分为氨基酸和多种黄酮类化合物,羽衣甘蓝叶提取物主要含有类胡萝卜素类叶黄素,并富含黄酮醇、花青素等类黄酮物质,欧蓍草提取物含有多种有机酸和黄酮苷类化合物。申请人经研究发现,添加埃及蓝睡莲花提取物、羽衣甘蓝叶提取物、欧蓍草提取物能够使得组合物在抗菌消炎祛痘的同时淡化痘印、修复皮肤损伤,作用机理可能在于:一方面,其含有的黄酮类化合物对细胞氧化应激存在保护作用,够延缓氧化损伤所造成的细胞死亡,进而促进痤疮消退后肌肤的正常修复,阻止非正常修复带来的痤疮后红斑、色素沉着和痤疮后瘢痕,另一方面,植物提取物含有的部分黄酮类化合物具有酪氨酸酶抑制活性,阻断黑色素生成,减轻痤疮后色素沉着;与此同时,植物提取物含有的氨基酸类小分子化合物能够很好渗透皮肤,从而对痤疮造成的皮肤损伤起到一定的修复作用、减轻炎症后的色素沉着等。
其次,本发明的组合物具有控油、预防痤疮产生的效果:壬二酸可以竞争性抑制产生二氢睾酮的酶过程,减少二氢睾酮因素诱发的皮肤油脂过多,水杨酸同样具有调节皮脂分泌的作用。油脂是痤疮丙酸杆菌繁殖的基础,通过抑制皮肤油脂的生成,能很好地预防痤疮地进一步产生;
其次,本发明的组合物具有去黑头的效果:黑头皮脂氧化以及混合沉积的色素颗粒而形成的小黑点,壬二酸可以逆转毛囊的角化程度,水杨酸具有疏通作用,可以溶解皮脂,从而让组合物具备改善黑头粉刺的效果;
其次,本发明的组合物具有良好的提亮肤色作用:葡萄糖不断与蛋白结合形成醣基化终末产物,醣基化会导致蛋白交联,细胞失去分裂能力。皮肤逐渐表现为棕黄色,而且韧性降低。本发明组合物中的白柳树皮提取物对胶原蛋白的产生和维持有重要作用,胶原蛋白促进能肌肤祛除暗黄,回复净白,除此之外,申请人在组合物中加入埃及蓝睡莲花提取物、羽衣甘蓝叶提取物和欧蓍草提取物,所述组合物能够显著改善色素沉着,恢复正常的肌肤颜色;
最后,本发明的组合物保湿性良好,温和不刺激,且质地轻盈、易于涂抹和吸收。现有的大部分含酸类(如壬二酸、水杨酸)护肤组合物都有着强烈刺激性,当成分配比不慎时,一方面易会出现刺激感,疼痛感,另一方面则会导致皮肤水分的流失,出现紧绷、起皮等现象。本申请的组合物通过天然成分和辅料的合理添加,成功解决了上述酸类组合物用于护肤品的缺陷,测试显示产品不仅具有上述多重功效,且质地清爽,不仅不会产生紧绷甚至于缺水的感觉,还起到了保湿的作用。
相比于目前市面上成分较为单一,只关注抗菌和舒缓作用的抗菌组合物,本发明通过上述组合物的制备,提供了一种温和不刺激、质地轻盈、易于涂抹和吸收,在祛痘同时具备减轻痤疮后红斑、治疗痤疮后色素沉着、缓解痤疮后瘢痕生成的祛痘组合物,其同时具有去黑头和提亮肤色的效果,能有效应对痤疮后遗症并多效护肤,从而实现在痤疮产生至消退的周期内进行全面治疗。
附图说明
图1:受试者使用组合物精华液(根据制备例1制备)前痤疮的照片(左图),使用2个月后面部痤疮情况的照片(右图)。
具体实施方式
下面结合具体实施例,对本发明作进一步详细的阐述,下述实施例不用于限制本发明,仅用于说明本发明。以下实施例中所使用的实验方法如无特殊说明,实施例中未注明具体条件的实验方法,通常按照常规条件,下述实施例中所使用的材料、试剂等,如无特殊说明,均可从商业途径得到。
制备例1
本实施例所述的化妆品组合物制作成一种水剂型化妆品,具体为一种抗痘修复精华液,其配方见表1。
本实施例所述的水剂型化妆品的制备方法,按以下步骤进行:
1.将苯氧乙醇和壬二酸加入丁二醇中,溶解均匀;
2.加入去离子水,加热至75摄氏度,降温至45摄氏度;
3.加入剩下的其他成分溶解均匀。
测试例
对祛痘修复组合物(各成分含量:壬二酸0.01-3份、红没药醇0.01-0.5份、白柳树皮提取物0.1-2份、埃及蓝睡莲花提取物0.1-2份、羽衣甘蓝叶提取物0.1-2份和欧蓍草提取物0.1-5份,纯化水补足至100份)进行如下实验测试:
测试对象:
随机选取油性皮肤,左右脸部都伴有轻度或中度的座疮,经医生评估,座疮等级2-3级、鼻翼两侧有明显可见黑头、面部皮肤干燥,屏障功能较差且伴有一定泛红症状的18-50岁中国健康男性/女性受试者30名。
测试方法:
采用前后对照的方法,对比:使用测试产品前、连续使用测试产品14天、连续使用测试产品28天的各项指标,通过产品使用前后的评价结进行比较,从而判断是否有效。
测量指标:
分别测量受试者皮肤以下指标:
1)全脸皮损积分总和;
2)痤疮处Visia-CR位置红度值、全脸Visia-CR皮肤红区面积占比;
3)痤疮处黑色素含量;
4)脸颊处皮肤油脂含量、全脸Visia-CR卟啉面积占比;
5)脸颊处经皮水分流失、皮肤角质层水分含量;
6)全脸Visia-CR毛孔面积占比;
7)全脸Visia-CR皮肤颜色L值、全脸Visia-CR皮肤颜色ITA值;
8)鼻翼两侧黑头数量;
9)受试者自我评估。
测试结果如下:
表1全脸皮损积分总和(IGA)
痤疮以面部的粉刺、丘疹、脓疱、结节等多形性皮损为特点,因此全脸皮损积分总和能很好地反映组合物治疗痤疮的效果。
从上表1可以看出,使用该测试例制备的抗痘修复组合物后,面部皮损面积明显减少,反映该组合物起到了很好的痤疮初期治疗效果。
表2痤疮处Visia-CR红度值、全脸Visia-CR皮肤红区面积占比
从上表2可以看出,使用该测试例制备的抗痘修复组合物,不仅对于痤疮处红斑有着改善效果,能有效缓解红色痘印的产生,还起到了一定的全脸舒缓效果,对于脸部皮肤发炎、泛红等也有很好的效果。
表3痤疮处黑色素含量
从上表3可以看出,使用该测试例制备的抗痘修复组合物,能减少痤疮部位黑色素沉着,防止黑色痘印的产生。
表4脸颊处皮肤油脂含量、全脸Visia-CR卟啉面积占比
油脂是致痤疮细菌繁殖的基础,皮肤油脂量高,则更易产生痤疮。卟啉是寄生于毛囊的一些细菌的代谢产物,卟啉面积占比可以反映出致痤疮细菌的生长和繁殖情况。
从上表4可以看出,使用该测试例制备的抗痘修复组合物,能起到很好的肌肤控油作用,对痤疮细菌也有着显著的杀伤性。不仅能对痤疮的治疗产生积极效果,还有有效预防痤疮进一步产生。
表5脸颊处经皮水分流失、皮肤角质层水分含量
从上表5可以看出,使用该测试例制备的抗痘修复组合物不仅不会产生紧绷、缺水的感觉,还显著降低了脸颊处经皮水分流失,增加了皮肤角质层水分含量,起到了很好的保湿作用。
表6全脸Visia-CR毛孔面积占比
从上表6可以看出,使用该测试例制备的抗痘修复组合物对皮肤的毛孔有一定的收缩作用,有助于缓解由于痤疮产生的毛孔粗大等后遗症,预防痤疮的进一步产生。
表7全脸Visia-CR皮肤颜色L值、全脸Visia-CR皮肤颜色ITA值
Visia-CR的L值和ITA值均反映了皮肤的亮度,ITA值是与L值相关的函数,ITA值越高,黄度越低,皮肤越亮白。
从上表7可以看出,使用该测试例制备的抗痘修复组合物具有良好的肤色提亮作用。
表8鼻翼两侧黑头数量
从上表8可以看出,使用该测试例制备的抗痘修复组合物能显著改善黑头情况。
表9受试者自我评估
对参加测试的受试者进行问卷调查,问卷中,对于问题,1分为“非常不同意”、2分为“不同意”、3分为“一般”、4分为“同意”、5分为“非常同意”。
表9显示了对相关问卷问题,选择4分为“同意”和5分为“非常同意”的人数占比。
从上表9可以看出,该组合物温和不刺激,且质地轻盈、易于涂抹和吸收,受试者主观也认可产品的控油效果,并对该组合物的祛痘、去痘印、保湿等等各项效果感到满意。
可以看出,本发明所述祛痘中,同时含有壬二酸、红没药醇、白柳树皮提取物、埃及蓝睡莲花提取物、羽衣甘蓝叶提取物成分和欧蓍草提取物时,能在祛痘同时减轻痤疮后红斑、治疗痤疮后色素沉着,且具有去黑头和提亮肤色的效果。与此同时,该组合物保湿效果良好,温和不刺激、质地轻盈、易于涂抹和吸收,较好实现在痤疮产生至消退的周期的全面治疗。
最后应当说明的是,以上内容仅用以说明本发明的技术方案,而非对本发明保护范围的限制,本领域的普通技术人员对本发明的技术方案进行的简单修改或者等同替换,均不脱离本发明技术方案的实质和范围。
Claims (10)
1.一种外用的化妆品组合物,其特征在于,该组合物包含:
壬二酸、红没药醇、白柳树皮提取物、埃及蓝睡莲花提取物、羽衣甘蓝叶提取物和欧蓍草提取物。
2.根据权利要求1所述的化妆品组合物,其特征在于,以重量份数计,该组合物包含:
壬二酸0.01-30份、红没药醇0.01-2份、白柳树皮提取物0.01-5份、埃及蓝睡莲花提取物0.01-5份、羽衣甘蓝提取物0.01-5份和欧蓍草提取物0.1-5份。
3.根据权利要求1所述的化妆品组合物,其特征在于,以重量份数计,该组合物包含:
壬二酸0.1-20份、红没药醇0.01-1.5份、白柳树皮提取物0.1-4份、埃及蓝睡莲花提取物0.1-3份、羽衣甘蓝提取物0.1-3份和欧蓍草提取物0.1-3份。
4.根据上述任一权利要求所述的化妆品组合物,其特征在于,该组合物还可以包含其他辅料。
5.根据权利要求4所述的祛痘修护组合物,其特征在于,所述的辅料可以选自保湿剂、乳化剂、发泡剂、pH调节剂、防腐剂和增稠剂中的一种或一种以上。
6.根据权利要求5所述的化妆品组合物,其特征在于,所述的保湿剂选自甘油、丙二醇、1,3丁二醇、1,2己二醇、戊二醇、双丙甘醇、海藻糖、甜菜碱、泛醇、烟酰胺、麦芽糖、β-葡聚糖、乳酸钠、聚乙烯吡咯烷酮、聚季铵盐-51、山梨醇、辛甘醇、乙基己基甘油、PEG-200、PEG-400、甘油聚醚-26中的一种或一种以上;所述乳化剂选自鲸蜡硬脂醇、鲸蜡硬脂醇聚醚-21、甘油硬脂酸酯、PEG-100硬脂酸酯、PEG-15甘油硬脂酸酯、PEG-20甘油硬脂酸酯、PEG-30甘油硬脂酸酯、PEG-40甘油硬脂酸酯、聚山梨醇酯-20、聚山梨醇酯-40、聚山梨醇酯-60、聚山梨醇酯-80、聚山梨醇酯-85、聚甘油-10二异硬脂酸酯、聚甘油-10二硬脂酸酯、聚甘油-10肉豆蔻酸酯、聚甘油-10异硬脂酸酯、聚甘油-10月桂酸酯、聚甘油-10硬脂酸酯、聚甘油-10油酸酯、聚甘油-5硬脂酸酯、山嵛醇聚醚-10、山嵛醇聚醚-20、山嵛醇聚醚-25、山嵛醇聚醚-30、鲸蜡硬脂基葡糖苷和山梨坦橄榄油酸酯中的一种或一种以上;所述发泡剂选自椰油酰胺丙基甜菜碱、椰油酰甘氨酸钠、椰油酰氨基丙酸钠,椰油酰羟乙磺酸酯钠、月桂醇聚醚硫酸酯钠、月桂醇聚醚硫酸酯铵、月桂醇硫酸酯钠、椰油酰胺丙基羟基磺基甜菜碱、月桂酰肌氨酸钠、月桂酸钾、甲基椰油酰基牛磺酸钠、甲基月桂酰基牛磺酸钠、月桂醇聚醚-6羧酸钠、月桂醇聚醚-16、癸基葡糖苷、月桂基羟基磺基甜菜碱、椰油酰两性基二乙酸二钠中的一种或一种以上;所述pH调节剂选自柠檬酸、柠檬酸钠、氢氧化钠、脱氢乙酸钠钾的一种或一种以上;所述防腐剂选自苯氧乙醇、对羟基苯乙酮、乙基己基甘油、辛甘醇、辛酰羟肟酸、1,2-己二醇和苯甲酸中的一种或一种以上;所述增稠选自卡波姆、丙烯酸(类)/C10-30烷醇丙烯酸酯交联聚合物、黄原胶、鞘氨醇单胞菌发酵提取物、羟乙基纤维素和丙烯酰二甲基牛磺酸铵/VP共聚物一种或一种以上;所述油脂为角鲨烷、异十六烷、碳酸二辛酯、氢化聚癸烯、氢化聚异丁烯、硅油、辛酸癸酸甘油三酯和异壬酸异壬酯中的一种或一种以上。
7.一种根据权利要求1-6任意一项所述的化妆品组合物的应用,其特征在于,用于制备祛痘、淡化痘印、修复皮肤损伤的化妆品的用途。
8.一种根据权利要求1-6任意一项所述的化妆品组合物的应用,其特征在于,将所述组合物用于制备水剂型化妆品、乳剂型化妆品、凝胶剂化妆品、敷贴型化妆品、气雾剂型化妆品及粉剂型化妆品。
9.一种祛痘修护精华,其特征在于,以祛痘修护组合物的重量份数计,包含以下组分:
壬二酸0.01-3份、红没药醇0.01-0.5份、白柳树皮提取物0.1-2份、埃及蓝睡莲花提取物0.1-2份、羽衣甘蓝叶提取物0.1-2份和欧蓍草提取物0.1-5份;
辅料:水80-98份,甜菜碱1-5份,1,3-丁二醇1-5份,苯氧乙醇0.5-1份。
10.一种祛痘洁面慕斯,其特征在于,以祛痘修护组合物的重量份数计,包含以下组分:
壬二酸0.1-2份、红没药醇0.1-0.5份、白柳树皮提取物0.1-2份、埃及蓝睡莲花提取物0.1-2份、羽衣甘蓝叶提取物0.1-2份和欧蓍草提取物0.1-2份;
辅料:水35-83份,椰油酰氨基丙酸钠10-30份,癸基葡糖苷2-10份,月桂醇聚醚-6羧酸钠2-10份,柠檬酸0.1-1份,甜菜碱1-5份,1,3-丁二醇1-5份,苯氧乙醇0.5-1份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310860991.XA CN117017850A (zh) | 2023-07-13 | 2023-07-13 | 一种祛痘修复的外用化妆品组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310860991.XA CN117017850A (zh) | 2023-07-13 | 2023-07-13 | 一种祛痘修复的外用化妆品组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117017850A true CN117017850A (zh) | 2023-11-10 |
Family
ID=88621622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310860991.XA Pending CN117017850A (zh) | 2023-07-13 | 2023-07-13 | 一种祛痘修复的外用化妆品组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117017850A (zh) |
-
2023
- 2023-07-13 CN CN202310860991.XA patent/CN117017850A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5940986B2 (ja) | 美容的処置のためのハエジゴクの抽出物を含有する組成物 | |
CN106420488B (zh) | 一种新生滋养抗皱眼霜 | |
KR102033089B1 (ko) | 항균, 항염증, 피지감소, 각질박리 및 피부진정용 조성물 | |
WO2008139182A2 (en) | Skin care composition | |
CN100558340C (zh) | 葫芦科油用于抑制5α-还原酶活性的应用 | |
KR102314813B1 (ko) | 피부-윤광 화장품 조성물 | |
CN113171327A (zh) | 控油祛痘组合物及其应用 | |
JP2008143784A (ja) | 細胞増殖促進剤 | |
JP2003081749A (ja) | 皮膚外用剤 | |
CN111671692A (zh) | 一种祛痘组合物及其制备方法与应用 | |
KR20190023200A (ko) | 저자극성 피부 미백용 화장료 조성물 | |
JP5645344B2 (ja) | 外用剤組成物 | |
JP3590369B2 (ja) | クリプトタンシノンを含むニキビ予防及び治療用化粧料組成物 | |
US11918666B2 (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
CN103494737A (zh) | 一种以姜花作为抗衰老护肤因子的化妆品制剂及制备方法 | |
CN106860067B (zh) | 马达加斯加哈伦加那提取物的化妆和/或皮肤病学用途 | |
KR102443283B1 (ko) | 마이크로바이옴을 이용한 피부 장벽 개선 효과가 우수한 화장료 조성물 | |
CN111743826A (zh) | 一种祛斑抗皱保湿乳液 | |
CN108392444A (zh) | 一种微整全能水化妆品及其制备方法 | |
KR20090111980A (ko) | 천연물 추출물을 함유하는 여드름 개선용 화장료 조성물 | |
CN117017850A (zh) | 一种祛痘修复的外用化妆品组合物及其应用 | |
JP3987733B2 (ja) | 線維芽細胞賦活剤及びこれを含む皮膚外用剤 | |
KR100610951B1 (ko) | 죽여추출물을 함유한 피부외용제 | |
JP4076477B2 (ja) | 皮膚外用剤 | |
JP2004307437A (ja) | 老化防止用皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |